Last reviewed · How we verify

NCT04306757

Flow Controlled Ventilation in Cardiac Surgery

Completed NA Last updated 23 March 2021
What this trial tests

NA trial testing Evone in Respiration; Artificial in 54 participants. Completed in 2 March 2021.

Timeline
6 March 2020
Primary endpoint
2 March 2021
2 March 2021

Quick facts

Lead sponsorMedical University Innsbruck
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment54
Start date6 March 2020
Primary completion2 March 2021
Estimated completion2 March 2021
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Medical University Innsbruck

Who can join

Adults 18 to 99, any sex, with Respiration; Artificial or Positive-Pressure Respiration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial investigates effects of individualized (by compliance guided pressure settings) flow-controlled ventilation compared to best clinical practice pressure controlled ventilation in cardiac surgery requiring cardiopulmonary bypass.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Flow-controlled ventilation - a new and promising method of ventilation presented with a review of the literature.
    Bialka S, Palaczynski P, Szuldrzynski K, Wichary P, et al · · 2022 · cited 14× · PMID 35142160 · DOI 10.5114/ait.2022.112889
  2. Postoperative pulmonale Komplikationen nach chirurgischen Eingriffen
    Spraider P, Abram J. · · 2021

Verify or expand the search:

Other trials of Evone

Trials testing the same drug.

Other Medical University Innsbruck trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04306757.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing